EmulTech

What EmulTech does

Emultech BV is a Netherlands-based private pharmaceutical technology company founded in 2009 and headquartered at High Tech Campus 9 in Eindhoven. The company has developed a patented microfluidic emulsification platform for the continuous production of monodisperse nano- and microparticles across a size range from nano to 350 microns. Its core technology centers on a proprietary chip architecture with up to 100 parallel microfluidic channels that work in concert to produce uniform emulsion droplets in a fully controlled and scalable manner, addressing a long-standing bottleneck in scaling conventional batch emulsification processes for pharmaceutical applications.

The platform is organized into three integrated phases—Discovery (modeling-assisted formulation transfer to target product profile), Pre-clinical (parallelized scale-up through chip channel multiplication), and Clinical Production (cGMP-compliant aseptic manufacturing). Emultech holds ISO 9001 certification from DEKRA, designs its clinical production system to comply with FDA 21 CFR Part 11 standards, and reports producing several kilograms of microspheres weekly from a single chip. The technology supports oil-in-water and water-in-oil emulsification as well as hydrodynamic flow focusing, serving applications including long-acting release injectables, dermal fillers, embolization agents, wound healing hydrogels, and targeted drug delivery (tumor and immune system targeting).

Emultech generates revenue through a combination of professional services (custom formulation, development, and manufacturing), licensing and development arrangements for joint product development, and managed-services-style joint ventures. The company pursues an enterprise field sales motion supplemented by event-driven marketing at conferences such as the Microsphere Summit, ACE Aesthetics Conference, and CRS Annual Meeting. Its customer base spans pharmaceutical companies, medical device manufacturers, biotech firms, and academic institutions. A core strategic initiative is the November 2021 Bone-Tech joint venture with Osteo-Pharma, which is developing an extended-release microsphere therapy for osteoarthritis of the knee under a 505(b)(2) regulatory pathway.

Name

EmulTech

Legal name

Emultech BV

Website

https://renehansen.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Emultech BV is a Netherlands-based company that has developed a patented microfluidic emulsification platform for continuous production of monodisperse microspheres and nanoparticles, primarily serving pharmaceutical and medical device companies developing controlled-release drug delivery products and injectable therapies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Microfluidic Encapsulation Equipment

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)

akta.pro primary industry

Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ)

akta.pro secondary industries

Delivery Systems & Encapsulation (Microencapsulation, Liposomes, Emulsions, Beadlets, Spray-Dried) (AFAJAKAL), Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors) (HLAAAJAC)

Keywords

• Microfluidic emulsification equipment
• Pharmaceutical encapsulation systems
• Monodisperse microsphere production
• Controlled release drug delivery
• CGMP particle manufacturing

Headquarters

HQ city

Eindhoven

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Microsphere Solutions Provider: Providing microsphere solutions as a provider, offering formulation, development and manufacturing services for pharma, biotech and medical device companies
2. Product Development Collaboration: Joint product development collaborations with partners, structured through license and development agreements
3. Joint Venture Revenue: Joint venture arrangements such as Bone-Tech for development and commercialization of specific therapeutic products

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Emultech supplies scaled cGMP-ready pharmaceutical microfluidic encapsulation equipment and provides formulation, development, and manufacturing services for monodisperse nano- and microparticles. Its patented microfluidic platform continuously produces microspheres, hydrospheres, and polymeric nanoparticles in a size range from nano to 350 microns for controlled release drug delivery, medical device, and targeted delivery applications. Engagement models span products and solutions provider through joint ventures such as Bone-Tech with Osteo-Pharma.

Product overview

EmulTech offers a microfluidic emulsification technology platform for producing monodisperse particles across the nano-to-350 micron size range. The platform consists of three integrated phases: Discovery (modeling-assisted formulation assessment), Pre-clinical (scale-up through parallelization of up to 100 channels), and Clinical Production (cGMP-compliant manufacturing at scale). The company produces multiple particle product categories including microspheres, hydrospheres, and polymeric nanoparticles for applications in controlled release drug delivery, targeted delivery, and medical devices (dermal fillers, embolization, wound healing). EmulTech's proprietary continuous production system enables instant scalability and superior control of particle properties including monodispersity, size, circularity, morphology, and encapsulation efficiency.

Differentiator

Problem solved

Functional benefit

Products and services

• Microfluidic Emulsification Platform

Quantifiable outcome

• Reduced waste of expensive raw materials due to no sieving requirement
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Osteo-PharmacoreStrategic or Co-development Partner · 17 November 2021Joint venture called Bone-Tech to develop OsteoActivator microspheres treatment for osteoarthritis of the knee. Combines Osteo-Pharma's novel combination drug therapy with Emultech's microfluidics microspheres technology. Product targets subchondral bone remodelling via intraosseous injection. Plans to pursue 505(b)(2) regulatory strategy for clinical trials.
• CDMOs (Contract Development and Manufacturing Organizations)coreChannel Partner/ Reseller/ DistributorPartnership with range of CDMOs incorporating Emultech's cGMP system to provide fill and finish capabilities for clinical production of parenteral and other drug products.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Dolomite Microfluidics: Dolomite Microfluidics (part of Blacktrace Holdings) designs and manufactures microfluidic chips and systems for particle generation, including monodisperse emulsions, droplets and microparticles used in pharma R&D. It is the closest direct competitor to EmulTech's microfluidic emulsification platform, serving overlapping pharma and academic customers.
• Phosphorex: Phosphorex is a US-based CDMO specialised in microsphere and nanoparticle drug delivery, offering formulation development, GMP manufacturing and particle engineering services. It directly overlaps EmulTech's core offering of controlled-release and targeted-delivery particle production for pharma and biotech customers.
• Syrris (Blacktrace): Syrris, part of Blacktrace, develops continuous-flow microfluidic reactors including the Asia and Atlas systems used for nanoparticle and emulsion production in pharma R&D. It competes head-to-head with EmulTech's Discovery and Pre-clinical platforms for microfluidic emulsion and particle generation customers.

Broad incumbents

• Particle Sciences (Lubrizol Life Science): Particle Sciences, part of Lubrizol Life Science, is a CDMO focused on complex drug delivery including microspheres, nanoparticles and nanoemulsions for pharma and biotech. It offers broader formulation, analytical and GMP manufacturing services than EmulTech, but serves the same controlled-release and targeted-delivery customer base.
• Evonik (Pharma & Healthcare / Resomer): Evonik's Health Care business manufactures biodegradable polymers (Resomer PLGA, PLA, PCL) used in long-acting injectable microspheres and supplies GMP manufacturing services. As the dominant polymer supplier for the microsphere industry, Evonik is both an indirect upstream enabler and a potential competitor to EmulTech's particle engineering services.
• Catalent: Catalent is a global pharma CDMO offering formulation development, softgel and oral/injectable manufacturing including controlled-release and biologics encapsulation services. It competes with EmulTech for pharma outsourcing budgets through broader scale and a much wider service portfolio, though without EmulTech's microfluidic particle-engineering specialisation.
• Lonza: Lonza is one of the world's largest pharma CDMOs, offering mammalian and microbial biologics manufacturing as well as particle-based drug delivery services. Its scale, regulatory expertise and breadth make it a default competitor in pharma outsourcing RFPs that EmulTech must also win for controlled-release injectable work.
• Ashland: Ashland supplies pharmaceutical excipients, polymers and drug delivery solutions used in controlled-release and topical formulations. While primarily a materials supplier, its pharma specialities business overlaps with EmulTech's polymer-based microsphere portfolio and competes for similar pharma development budgets.
• Corbion (TotalEnergies Corbion): Corbion is a major producer of PLA biopolymers and lactic-acid-based biomaterials used in medical devices, drug delivery and microsphere applications. It supplies raw materials into the same controlled-release injectable value chain EmulTech serves and is a relevant competitor in resorbable polymer-based particle platforms.

Emerging players

• Elveflow: Elveflow is a French microfluidic instrument company offering flow-control systems, microfluidic chips and droplet-generation modules used in academic and industrial research labs. It is a smaller, more academic-focused emerging player that overlaps with EmulTech's microfluidic particle-generation toolkit at the Discovery/Pre-clinical stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/emultech
• LinkedInlinkedin.com/company/emultech-bv?originalSubdomain=nl

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EmulTech